PROTEASE INHIBITORS AND SOLIFENACIN
Ketoconazole increases solifenacin levels 2- to 3-fold by inhibiting CYP3A4. The manufacturers say other potent CYP3A4 inhibitors (such as the protease inhibitors) will have the same effect.
The manufacturers limit the daily dose of solifenacin to 5 mg if it is given with potent inhibitors of CYP3A4. In addition, in patients with severe renal impairment or moderate hepatic impairment, concurrent use is contraindicated.
The manufacturers limit the daily dose of solifenacin to 5 mg if it is given with potent inhibitors of CYP3A4. In addition, in patients with severe renal impairment or moderate hepatic impairment, concurrent use is contraindicated.